FDA Approves Empagliflozin for Type 2 Diabetes

Share this content:
FDA Approves Empagliflozin for Type 2 Diabetes
FDA Approves Empagliflozin for Type 2 Diabetes

(HealthDay News) — Empagliflozin (Jardiance) has been approved by the FDA to treat type 2 diabetes, the agency said in a news release.

Jardiance, a sodium glucose co-transporter 2 (SGLT2) inhibitor, is designed to block reabsorption of glucose by the kidneys. Its safety and effectiveness were evaluated in clinical studies involving 4,480 people with type 2 diabetes. 

The drug should not be used to treat type 1 diabetes, in people with severe kidney impairment, among people with increased ketones in the blood or urine or in people on dialysis, the FDA said.

The agency said it has ordered several postmarketing studies of the new drug, including an evaluation of its effects on the cardiovascular system. The most common side effects are urinary tract infection and female genital infection. 

The drug also may cause dehydration, leading to a significant drop in blood pressure.

"Jardiance provides an additional treatment option for the care of patients with type 2 diabetes," Curtis Rosebraugh, MD, MPH, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, said in a statement. 

"It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes."

Jardiance is distributed by Boehringer Ingelheim Pharmaceuticals, based in Ridgefield, Conn.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters



CME Focus